Type 2 diabetes mellitus
Conditions
Interventions
repaglinide 150mg for 4 months. If HbA1c is more than 7.0%, other hypoglycemic agents, is consider to add.
Glimepiride 0.5mg for 4 months. If HbA1c is more than 7.0%, other hypoglycemic agents, is
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)before test registration -vildagliptin 100mg or linagliptin 5mg for at least one month and outpatient 2)HbA1c :more than 7.0%, less than 11% 3)Type 2 diabetes 4)Pts with written IC 5)Age more than 20, less than 85
Exclusion criteria
Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 5)pregnacy 6)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride 7)Patients judged by the investigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate of postprandial glucose after treatment with repaglinide or glimepiride | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Achievment rate of <7.0% at 4 months 2)Achievement rate of <7.0% at 8months 3)Renal function 4)glycemic control 5)lipid control 6)Achievement rate of <6.5%,<180mg/dl of PPG | — |
Countries
Japan
Contacts
Public ContactJun Suzuki
Yokohama City University Medical Center Department of Endocrinology and Diabetes
Outcome results
None listed